Mirabegron - a beta-3 adrenergic agonist for overactive bladder syndrome: A review

Abstract

Overactive bladder (OAB) is a urological disorder with symptoms of frequency urgency and incontinence, which substantially affects quality of life. The prevalence of OAB increased with old age Caucasians, White and Asians. The main etiological factor for OAB is lifestyle modification and stress, embarrassment, frustration, etc. OAB can be treated with anticholinergic (first-line treatment) and adrenergic agonists. Anticholinergic agents are first-line drug for the treatment of OAB; unfortunately, antimuscarinic agents are not effective in controlling OAB symptoms. In the year, 2012 US-FDA approved first β₃ adrenergic agonist (mirabegron) for the treatment of OAB. Mirabegron was developed by Astellas Pharma, Japan and introduced into the market in 2011. Recommended adult dose of mirabegron is 25 mg/day for 8 weeks. Mirabegron is a beta agonist, which can increase a blood pressure, hence it was not recommended to patients who have uncontrolled blood pressure. This review is mainly focused to discuss about mirabegron for the treatment of OAB.